Q3 EPS Estimate for Outlook Therapeutics Lifted by Analyst

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Free Report) - Stock analysts at Brookline Capital Management raised their Q3 2025 EPS estimates for shares of Outlook Therapeutics in a report issued on Tuesday, May 27th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.29) for the quarter, up from their previous estimate of ($0.35). The consensus estimate for Outlook Therapeutics' current full-year earnings is ($2.27) per share. Brookline Capital Management also issued estimates for Outlook Therapeutics' Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($1.62) EPS and FY2027 earnings at $0.97 EPS.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.15.

OTLK has been the subject of a number of other research reports. Guggenheim restated a "buy" rating on shares of Outlook Therapeutics in a research note on Tuesday, May 20th. HC Wainwright lowered their target price on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. Chardan Capital reiterated a "neutral" rating and set a $3.00 target price on shares of Outlook Therapeutics in a research note on Tuesday, February 18th. Finally, Ascendiant Capital Markets lowered their target price on shares of Outlook Therapeutics from $33.00 to $24.00 and set a "buy" rating for the company in a research note on Monday, February 24th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $10.20.

Outlook Therapeutics Price Performance

Shares of NASDAQ:OTLK traded up $0.05 during midday trading on Friday, reaching $1.85. The company had a trading volume of 1,205,337 shares, compared to its average volume of 774,205. The stock's fifty day moving average price is $1.48 and its 200-day moving average price is $1.87. The stock has a market capitalization of $62.10 million, a P/E ratio of -0.25 and a beta of 0.39. Outlook Therapeutics has a one year low of $0.87 and a one year high of $9.25.

Hedge Funds Weigh In On Outlook Therapeutics

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. grew its position in shares of Outlook Therapeutics by 34,936.7% during the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company's stock worth $32,000 after acquiring an additional 17,119 shares during the last quarter. Commonwealth Equity Services LLC bought a new position in shares of Outlook Therapeutics during the fourth quarter worth about $48,000. Jane Street Group LLC grew its position in shares of Outlook Therapeutics by 133.9% during the fourth quarter. Jane Street Group LLC now owns 26,218 shares of the company's stock worth $50,000 after acquiring an additional 15,008 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Outlook Therapeutics by 44.8% during the fourth quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company's stock worth $56,000 after acquiring an additional 9,211 shares during the last quarter. Finally, Scotia Capital Inc. grew its position in shares of Outlook Therapeutics by 124.4% during the fourth quarter. Scotia Capital Inc. now owns 73,989 shares of the company's stock worth $140,000 after acquiring an additional 41,023 shares during the last quarter. Institutional investors own 11.20% of the company's stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.